LENSAR Reports Q4 Revenue of $16.03M, Down Year-over-Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Reports Q4 revenue $16.03M vs. $16.73M last year. "While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so," said CEO Nick Curtis. "We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR to continue growing its recurring revenue base and its overall business."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNSR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNSR
Wall Street analysts forecast LNSR stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 6.000
Low
15.00
Averages
15.00
High
15.00
Current: 6.000
Low
15.00
Averages
15.00
High
15.00
About LNSR
LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LENSAR Q1 2026 Earnings Call Insights
- Revenue Shift: LENSAR reported total revenue of $13.4 million for Q1 2026, a 5% decline year-over-year, yet recurring revenue rose to $12.6 million, representing 94% of total revenue, indicating a positive shift in revenue structure.
- Stable Market Share: The company's U.S. procedure market share stood at 23.4% at the end of Q1, consistent with the previous year, demonstrating LENSAR's ability to maintain a stable position in a competitive market.
- Decline in System Sales: System sales revenue was approximately $800,000 this quarter, significantly down from $2.6 million in the prior year, reflecting challenges in equipment sales, although the growth in recurring revenue provides a buffer for future stability.
- Cautious Future Outlook: Management did not provide formal financial guidance, with CEO Curtis indicating that recovery will take several quarters, and he expects 2027 to be a pivotal year for the company's rebound, emphasizing confidence in future growth.
See More
LENSAR Q1 Earnings Report Analysis
- Disappointing Earnings: LENSAR reported a Q1 GAAP EPS of $0.00, missing expectations by $0.18, indicating challenges in profitability that could undermine investor confidence.
- Revenue Performance: The company generated $13.4 million in revenue for the quarter, a 5.6% year-over-year decline, which, while in line with expectations, raises concerns about long-term growth prospects amid ongoing revenue contraction.
- Installation Progress: As of March 31, 2026, LENSAR installed 205 ALLY Systems, adding 7 units, demonstrating gradual expansion capabilities in recovering market demand, although a backlog of 11 pending installations indicates delays in delivery cycles.
- Total System Growth: The combined installed base of LENSAR Laser Systems and ALLY Systems reached approximately 440 units as of March 31, 2026, reflecting a 12% increase compared to the same period in 2025, showcasing the company's gradual recovery and growth potential in the market.
See More
LENSAR Reports Q4 2025 Earnings with Mixed Results
- Revenue Performance: LENSAR reported total revenue of $16 million in Q4 2025, a 4% year-over-year decline, despite a 9% increase for the full year, indicating volatility and challenges in the market.
- Recurring Revenue Growth: Recurring revenue increased by 15% in 2025, totaling $46.3 million, reflecting the company's success in expanding its installed base and increasing system utilization, which enhances future revenue stability.
- Procedure Volume Growth: The company experienced a 20% increase in procedure volume in Q4 2025 and a 22% increase for the full year, surpassing 206,000 globally, indicating strong demand and market share growth in the surgical market.
- Gross Margin Changes: Gross margin for Q4 2025 was 43%, up from 42% in Q4 2024, but the full-year margin declined to 46%, highlighting pressures on profitability from inflation and tariffs.
See More
LENSAR Q4 2025 Earnings: Strategic Reset and Growth Outlook
- Acquisition Termination Impact: LENSAR's termination of the Alcon acquisition due to FTC opposition, as stated by CEO Nicholas Curtis, represents a pragmatic decision after a year of effort, marking a strategic reset for the company as it refocuses on independent operations, which is expected to influence future market strategies and resource allocation.
- Market Share Growth: By the end of 2025, LENSAR increased its U.S. procedure market share from 14% to 23.4%, while the installed base of ALLY systems grew nearly 50% compared to 2024, indicating strong growth momentum in the surgical equipment market, which is anticipated to further enhance its competitive position.
- Financial Performance Overview: The company reported total revenue of $16 million for Q4 2025, reflecting a 4% year-over-year decline primarily due to lower system sales; however, recurring revenue grew by 17% to $12.7 million, demonstrating positive progress in stabilizing revenue sources, which is expected to lay a foundation for future financial health.
- 2026 Outlook: CFO Thomas Staab forecasts an increase in gross margin to 46%-49% for 2026 and plans to limit cash operating expense growth to no more than 10%, indicating a cautious approach to cost control and commercial activities aimed at supporting future growth.
See More
LENSAR Reports 2025 Financial Results and Operational Updates
- Installed Base Growth: As of December 31, 2025, LENSAR's ALLY system installed base grew to approximately 200 units, representing a 48% increase over 2024, indicating strong market demand and recognition of the company's technology in the competitive cataract surgery market.
- Recurring Revenue Increase: Full-year recurring revenue exceeded $46.3 million, up 15% year-over-year, with a 17% increase in Q4 recurring revenue, demonstrating steady expansion in customer base and market share.
- Significant Procedure Volume Growth: Worldwide procedure volume increased by 22% in 2025 compared to 2024, with Q4 volume up 20% year-over-year, reflecting the growing appeal and acceptance of LENSAR's technology among surgeons.
- Improved Financial Performance: Although total revenue decreased by 4% in Q4 2025 compared to 2024, net loss significantly reduced to $1.5 million, showcasing the company's positive progress in cost control and operational efficiency.
See More
LENSAR Q4 Earnings Miss Expectations with Revenue Decline
- Disappointing Earnings: LENSAR reported a Q4 GAAP EPS of -$0.12, missing expectations by $0.05, indicating ongoing pressure on profitability that may affect investor confidence.
- Revenue Decline: The company posted revenue of $16.03 million, a 4.2% year-over-year decrease, falling short of the anticipated $20.3 million, reflecting challenges from weak market demand and increased competition.
- Installation Status: In Q4 2025, LENSAR placed 15 ALLY Robotic Cataract Laser Systems, with a backlog of 13 pending installations as of December 31, indicating bottlenecks in supply chain and installation capabilities despite a 48% growth in installed base.
- Adjusted EBITDA: The adjusted EBITDA for the quarter was $0.6 million, slightly up from $0.5 million in Q4 2024, suggesting improvements in cost control, yet overall profitability remains insufficient.
See More
LENSAR Q1 2026 Earnings Call Insights
- Revenue Shift: LENSAR reported total revenue of $13.4 million for Q1 2026, a 5% decline year-over-year, yet recurring revenue rose to $12.6 million, representing 94% of total revenue, indicating a positive shift in revenue structure.
- Stable Market Share: The company's U.S. procedure market share stood at 23.4% at the end of Q1, consistent with the previous year, demonstrating LENSAR's ability to maintain a stable position in a competitive market.
- Decline in System Sales: System sales revenue was approximately $800,000 this quarter, significantly down from $2.6 million in the prior year, reflecting challenges in equipment sales, although the growth in recurring revenue provides a buffer for future stability.
- Cautious Future Outlook: Management did not provide formal financial guidance, with CEO Curtis indicating that recovery will take several quarters, and he expects 2027 to be a pivotal year for the company's rebound, emphasizing confidence in future growth.
See More
LENSAR Q1 Earnings Report Analysis
- Disappointing Earnings: LENSAR reported a Q1 GAAP EPS of $0.00, missing expectations by $0.18, indicating challenges in profitability that could undermine investor confidence.
- Revenue Performance: The company generated $13.4 million in revenue for the quarter, a 5.6% year-over-year decline, which, while in line with expectations, raises concerns about long-term growth prospects amid ongoing revenue contraction.
- Installation Progress: As of March 31, 2026, LENSAR installed 205 ALLY Systems, adding 7 units, demonstrating gradual expansion capabilities in recovering market demand, although a backlog of 11 pending installations indicates delays in delivery cycles.
- Total System Growth: The combined installed base of LENSAR Laser Systems and ALLY Systems reached approximately 440 units as of March 31, 2026, reflecting a 12% increase compared to the same period in 2025, showcasing the company's gradual recovery and growth potential in the market.
See More
LENSAR Reports Q4 2025 Earnings with Mixed Results
- Revenue Performance: LENSAR reported total revenue of $16 million in Q4 2025, a 4% year-over-year decline, despite a 9% increase for the full year, indicating volatility and challenges in the market.
- Recurring Revenue Growth: Recurring revenue increased by 15% in 2025, totaling $46.3 million, reflecting the company's success in expanding its installed base and increasing system utilization, which enhances future revenue stability.
- Procedure Volume Growth: The company experienced a 20% increase in procedure volume in Q4 2025 and a 22% increase for the full year, surpassing 206,000 globally, indicating strong demand and market share growth in the surgical market.
- Gross Margin Changes: Gross margin for Q4 2025 was 43%, up from 42% in Q4 2024, but the full-year margin declined to 46%, highlighting pressures on profitability from inflation and tariffs.
See More
LENSAR Q4 2025 Earnings: Strategic Reset and Growth Outlook
- Acquisition Termination Impact: LENSAR's termination of the Alcon acquisition due to FTC opposition, as stated by CEO Nicholas Curtis, represents a pragmatic decision after a year of effort, marking a strategic reset for the company as it refocuses on independent operations, which is expected to influence future market strategies and resource allocation.
- Market Share Growth: By the end of 2025, LENSAR increased its U.S. procedure market share from 14% to 23.4%, while the installed base of ALLY systems grew nearly 50% compared to 2024, indicating strong growth momentum in the surgical equipment market, which is anticipated to further enhance its competitive position.
- Financial Performance Overview: The company reported total revenue of $16 million for Q4 2025, reflecting a 4% year-over-year decline primarily due to lower system sales; however, recurring revenue grew by 17% to $12.7 million, demonstrating positive progress in stabilizing revenue sources, which is expected to lay a foundation for future financial health.
- 2026 Outlook: CFO Thomas Staab forecasts an increase in gross margin to 46%-49% for 2026 and plans to limit cash operating expense growth to no more than 10%, indicating a cautious approach to cost control and commercial activities aimed at supporting future growth.
See More
LENSAR Reports 2025 Financial Results and Operational Updates
- Installed Base Growth: As of December 31, 2025, LENSAR's ALLY system installed base grew to approximately 200 units, representing a 48% increase over 2024, indicating strong market demand and recognition of the company's technology in the competitive cataract surgery market.
- Recurring Revenue Increase: Full-year recurring revenue exceeded $46.3 million, up 15% year-over-year, with a 17% increase in Q4 recurring revenue, demonstrating steady expansion in customer base and market share.
- Significant Procedure Volume Growth: Worldwide procedure volume increased by 22% in 2025 compared to 2024, with Q4 volume up 20% year-over-year, reflecting the growing appeal and acceptance of LENSAR's technology among surgeons.
- Improved Financial Performance: Although total revenue decreased by 4% in Q4 2025 compared to 2024, net loss significantly reduced to $1.5 million, showcasing the company's positive progress in cost control and operational efficiency.
See More
LENSAR Q4 Earnings Miss Expectations with Revenue Decline
- Disappointing Earnings: LENSAR reported a Q4 GAAP EPS of -$0.12, missing expectations by $0.05, indicating ongoing pressure on profitability that may affect investor confidence.
- Revenue Decline: The company posted revenue of $16.03 million, a 4.2% year-over-year decrease, falling short of the anticipated $20.3 million, reflecting challenges from weak market demand and increased competition.
- Installation Status: In Q4 2025, LENSAR placed 15 ALLY Robotic Cataract Laser Systems, with a backlog of 13 pending installations as of December 31, indicating bottlenecks in supply chain and installation capabilities despite a 48% growth in installed base.
- Adjusted EBITDA: The adjusted EBITDA for the quarter was $0.6 million, slightly up from $0.5 million in Q4 2024, suggesting improvements in cost control, yet overall profitability remains insufficient.
See More
